Egetis Therapeutics AB (SE:EGTX)
FRANKFURT:EGTX
Want to see SE:EGTX full AI Analyst Report?
EGTX Stock Chart & Stats
kr5.26
-kr0.06(-1.13%)
―
--
Day’s Range― - ―
52-Week Rangekr3.63 - kr7.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)792.52K
Market Cap
kr2.45B
Enterprise Valuekr1.94B
Total Cash (Recent Filing)kr142.50M
Total Debt (Recent Filing)kr75.20M
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding464,947,240
10 Day Avg. Volume1,042,665
30 Day Avg. Volume792,519
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.87
Revenue Forecast (FY)kr587.67M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained TTM revenue growth of ~112% signals genuine commercial traction or milestone-driven receipts in orphan indications. Over 2–6 months this trend supports scaling operational leverage, validates market demand for specific assets and improves the potential path to sustainable topline-driven profitability.
Positive Gross MarginA positive gross margin (~14%) indicates underlying product or service economics that cover direct costs. For a biotech focused on orphan therapies, this suggests that once R&D and SG&A are controlled, incremental revenue can meaningfully flow to operating profit as programs commercialize and fixed costs are absorbed.
Manageable LeverageLeverage near 0.30 is relatively modest for a development-stage biotech, limiting near-term interest burdens and preserving flexibility. This structure gives management optionality for bridge financing or project funding over the next several months without excessive solvency pressure, assuming fundraising access.
Bears Say
Deep Cash BurnOperating and free cash flow are deeply negative (~-265M), indicating the company is consuming substantial cash to fund R&D and operations. Over the medium term this burn necessitates external financing or sharp cost cuts, raising dilution and liquidity risk which can materially constrain pipeline progression.
Capital ErosionShrinking equity and a severely negative ROE (~-98%) reflect capital erosion from sustained losses. This reduces the firm’s balance-sheet cushion, increases dependence on new capital raises, and may raise financing costs or dilute existing shareholders, impairing strategic flexibility over the coming quarters.
Highly Loss-makingNet losses multiple times revenue (net margin ~-592%) show the business remains far from profitability. Even with revenue growth, persistent large operating losses suggest structural cost or scale issues that must be addressed to achieve durable margins and free cash flow generation in the next 2–6 months.
Egetis Therapeutics AB News
EGTX FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest stock price was kr3.63 and its highest was kr7.07 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is kr2.45B.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 62 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Apr 29, 2026. The company reported -kr0.239 earnings per share for the quarter, missing the consensus estimate of -kr0.19 by -kr0.049.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,947,240 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -kr0.239 in its last earnings report, missing expectations of -kr0.19. Following the earnings report the stock price went up 0.173%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in SE:EGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Options Prices
Currently, No data available
---